513 related articles for article (PubMed ID: 17987788)
1. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
4. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
5. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ
J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606
[TBL] [Abstract][Full Text] [Related]
7. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
Costa L
Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
[TBL] [Abstract][Full Text] [Related]
12. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates in lung cancer: more than a palliative therapy?
Jahanzeb M; Hirsh V
Semin Oncol; 2010 Jun; 37 Suppl 1():S45-52. PubMed ID: 20682372
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Rosen LS; Gordon DH; Dugan W; Major P; Eisenberg PD; Provencher L; Kaminski M; Simeone J; Seaman J; Chen BL; Coleman RE
Cancer; 2004 Jan; 100(1):36-43. PubMed ID: 14692022
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
18. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
[TBL] [Abstract][Full Text] [Related]
19. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
20. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
Henk HJ; Kaura S; Teitelbaum A
J Med Econ; 2012; 15(1):195-204. PubMed ID: 22175657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
